The role of interferons in the treatment of multiple sclerosis.
IFN beta-1b clearly alters the course of disease in patients with relapsing-remitting MS, although the adverse effects of this agent may discourage some patients from continuing the therapy. Nurses can help patients with MS minimize adverse effects through teaching. A double-blind, placebo-controlled clinical trial in patients with relapsing-progressive MS will be started in 1995. It is hoped that IFN beta-1b will be effective in slowing the accumulation of CNS lesions in those with progressive MS.
Kelley
C L
CL
Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000276:immunology; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000276:immunology / Q000627:therapeutic use*; D007372:Interferons / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000451:nursing; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016207:Cytokines; D000068576:Interferon beta-1b; D016899:Interferon-beta; D007372:Interferons; D000068556:Interferon beta-1a